Fertifa, a London company that provides reproductive and hormonal health benefits through employers, has agreed to buy Tuune, a women's health startup that makes clinical decision-support software for hormonal care. The deal was reported on November 5, 2026, after first being reported by Sky News, and Fertifa confirmed it in a statement shared on LinkedIn.
The price was not disclosed. Reports describe the deal as agreed, and none of the sources says it has closed. Tuune founder Shardi Nahavandi said Fertifa would take Tuune's work forward and bring it to more people.
The purchase follows Fertifa's acquisition of reproductive health insurer Juniper Reproductive Health in July 2025. It extends the company's offering further into contraception and menopause care, alongside its original focus on fertility and family building.
What Tuune built
Tuune was founded in London in 2018, according to an analysis of the deal by Nelson Advisors. Its software is regulated as a clinical product. Patients complete a health assessment before an appointment, and the system uses a proprietary algorithm based on clinical research to give the clinician a report with evidence-based treatment options.
Fertifa said in its statement that Tuune's technology draws on thousands of scientific publications and assesses more than 70 symptoms, alongside a patient's medical history, to support clinical decisions on contraception and menopause. Tuune began with contraception and later extended the product to menopause, Nelson Advisors said. The company's own website describes the tool as built by doctors for doctors.
Fertifa said Tuune was founded on the belief that women's healthcare should reflect each person's symptoms, medical history and needs, and that finding the right contraception or menopause treatment can involve a lot of trial and error.
“I'm proud that Fertifa will take this work forward and help bring it to more people.”
The founder and the funding
Nahavandi founded Tuune. She said in comments carried by Femtech Insider that the company's mission had been to help women understand their bodies and hormones.
Tuune raised $4.6 million in October 2021 in a round led by Octopus Ventures, money intended to launch the product in the United States, and it has been backed by Google for Startups, according to Nelson Advisors. Public listings put its team at between 10 and 20 people, the same analysis said. Neither company has said what will happen to Tuune's staff or brand.
Why Fertifa is buying
Fertifa was founded in London in August 2019 by Tony Chen and Nick Kuan and began as a fertility benefits provider for employers. Eileen Burbidge, the venture investor, has been its executive director since January 2022, according to Nelson Advisors. Its employer clients include Lululemon and Meta, Femtech Insider reported, and it is the exclusive provider of Aviva UK's family planning and fertility benefit across many of the insurer's schemes, Nelson Advisors said.
The company raised £5 million (about $6.3 million) in a seed round in June 2023 led by Notion Capital and Triple Point Ventures, with EQT Foundation, Speedinvest and Passion Capital also taking part. Its earlier pre-seed round was led by Passion Capital, where Burbidge was a partner, Dealroom reported.
Burbidge said Fertifa and Tuune have always shared a commitment to making personalised, evidence-based healthcare more accessible, and linked the timing of the deal to the company's expansion to cover more underserved healthcare needs for employees. Fertifa's coverage has grown from fertility to contraception, menopause, endometriosis, polycystic ovary syndrome, mental health and other areas.
A tuck-in for workplace women's health
Buying Tuune gives Fertifa software that sits in front of a clinician, rather than another benefit to resell. Fertifa said the deal strengthens its portfolio across cycle health, fertility and menopause by bringing hormone-related clinical decision support onto its benefits platform.
Nelson Advisors described the transaction as a strategic tuck-in rather than a major consolidation of the sector. For Tuune, which raised its 2021 round to take its product to the US, the sale hands its technology to a company that already sells health benefits to large employers.




